173 related articles for article (PubMed ID: 35542387)
1. Soluble Receptor for Advanced Glycation End Products (sRAGE) Isoforms Predict Changes in Resting Energy Expenditure in Adults with Obesity during Weight Loss.
Popp CJ; Zhou B; Manigrasso MB; Li H; Curran M; Hu L; St-Jules DE; Alemán JO; Vanegas SM; Jay M; Bergman M; Segal E; Sevick MA; Schmidt AM
Curr Dev Nutr; 2022 May; 6(5):nzac046. PubMed ID: 35542387
[TBL] [Abstract][Full Text] [Related]
2. Modulation of soluble receptor for advanced glycation end products isoforms and advanced glycation end products in long-living individuals.
Scavello F; Tedesco CC; Castiglione S; Maciag A; Sangalli E; Veglia F; Spinetti G; Puca AA; Raucci A
Biomark Med; 2021 Aug; 15(11):785-796. PubMed ID: 34236256
[TBL] [Abstract][Full Text] [Related]
3. Assessment of EN-RAGE, sRAGE, and its isoforms: cRAGE, esRAGE in obese patients treated by moderate caloric restriction combined with physical activity conducted in hospital condition.
Kanikowska D; Kanikowska A; Strojny Z; Kawka E; Zawada A; Rutkowski R; Litwinowicz M; Sato M; Grzymisławski M; Bręborowicz A; Witowski J; Korybalska K
Cytokine; 2024 Aug; 180():156665. PubMed ID: 38823153
[TBL] [Abstract][Full Text] [Related]
4. Circulating levels of AGEs and soluble RAGE isoforms are associated with all-cause mortality and development of cardiovascular complications in type 2 diabetes: a retrospective cohort study.
Sabbatinelli J; Castiglione S; Macrì F; Giuliani A; Ramini D; Vinci MC; Tortato E; Bonfigli AR; Olivieri F; Raucci A
Cardiovasc Diabetol; 2022 Jun; 21(1):95. PubMed ID: 35668468
[TBL] [Abstract][Full Text] [Related]
5. Circulating soluble RAGE isoforms are attenuated in obese, impaired-glucose-tolerant individuals and are associated with the development of type 2 diabetes.
Miranda ER; Somal VS; Mey JT; Blackburn BK; Wang E; Farabi S; Karstoft K; Fealy CE; Kashyap S; Kirwan JP; Quinn L; Solomon TPJ; Haus JM
Am J Physiol Endocrinol Metab; 2017 Dec; 313(6):E631-E640. PubMed ID: 28811295
[TBL] [Abstract][Full Text] [Related]
6. Enhanced expression of receptor for advanced glycation end-products is associated with low circulating soluble isoforms of the receptor in Type 2 diabetes.
Tam XH; Shiu SW; Leng L; Bucala R; Betteridge DJ; Tan KC
Clin Sci (Lond); 2011 Jan; 120(2):81-9. PubMed ID: 20726839
[TBL] [Abstract][Full Text] [Related]
7. Two soluble isoforms of receptors for advanced glycation end products (RAGE) in carotid atherosclerosis: the difference of soluble and endogenous secretory RAGE.
Moriya S; Yamazaki M; Murakami H; Maruyama K; Uchiyama S
J Stroke Cerebrovasc Dis; 2014; 23(10):2540-2546. PubMed ID: 25282185
[TBL] [Abstract][Full Text] [Related]
8. Divergent Changes in Plasma AGEs and sRAGE Isoforms Following an Overnight Fast in T1DM.
Miranda ER; Fuller KNZ; Perkins RK; Beisswenger PJ; Farabi SS; Quinn L; Haus JM
Nutrients; 2019 Feb; 11(2):. PubMed ID: 30781793
[TBL] [Abstract][Full Text] [Related]
9. Endogenous secretory RAGE increases with improvements in body composition and is associated with markers of adipocyte health.
Miranda ER; Fuller KNZ; Perkins RK; Kroeger CM; Trepanowski JF; Varady KA; Haus JM
Nutr Metab Cardiovasc Dis; 2018 Nov; 28(11):1155-1165. PubMed ID: 30297199
[TBL] [Abstract][Full Text] [Related]
10. AGEs/sRAGE, a novel risk factor in the pathogenesis of end-stage renal disease.
Prasad K; Dhar I; Zhou Q; Elmoselhi H; Shoker M; Shoker A
Mol Cell Biochem; 2016 Dec; 423(1-2):105-114. PubMed ID: 27714575
[TBL] [Abstract][Full Text] [Related]
11. Modulation of soluble receptor for advanced glycation end-products (RAGE) isoforms and their ligands in healthy aging.
Scavello F; Zeni F; Tedesco CC; Mensà E; Veglia F; Procopio AD; Bonfigli AR; Olivieri F; Raucci A
Aging (Albany NY); 2019 Mar; 11(6):1648-1663. PubMed ID: 30903794
[TBL] [Abstract][Full Text] [Related]
12. Metabolic Derangements Contribute to Reduced sRAGE Isoforms in Subjects with Alzheimer's Disease.
Fuller KNZ; Miranda ER; Thyfault JP; Morris JK; Haus JM
Mediators Inflamm; 2018; 2018():2061376. PubMed ID: 29681765
[TBL] [Abstract][Full Text] [Related]
13. Endogenous secretory RAGE but not soluble RAGE is associated with carotid atherosclerosis in type 1 diabetes patients.
Katakami N; Matsuhisa M; Kaneto H; Matsuoka TA; Sakamoto K; Yasuda T; Yamasaki Y
Diab Vasc Dis Res; 2008 Sep; 5(3):190-7. PubMed ID: 18777492
[TBL] [Abstract][Full Text] [Related]
14. Soluble Receptor for Advanced Glycation End Products and Its Forms in COVID-19 Patients with and without Diabetes Mellitus: A Pilot Study on Their Role as Disease Biomarkers.
Dozio E; Sitzia C; Pistelli L; Cardani R; Rigolini R; Ranucci M; Corsi Romanelli MM
J Clin Med; 2020 Nov; 9(11):. PubMed ID: 33238596
[TBL] [Abstract][Full Text] [Related]
15. Metabolic dysfunction in Emirati subjects in Abu Dhabi: Relationship to levels of soluble RAGEs.
Abdulle A; Inman CK; Saleh A; Noshi M; Galani D; Abdelwareth L; Alsafar H; Elfatih A; Al Shamsi H; Ali R; Li H; Ramasamy R; Schmidt AM; Benbarka MM; Hassan MH
J Clin Transl Endocrinol; 2019 Jun; 16():100192. PubMed ID: 31080742
[TBL] [Abstract][Full Text] [Related]
16. Effect of insulin on the soluble receptor for advanced glycation end products (RAGE).
Lam JK; Wang Y; Shiu SW; Wong Y; Betteridge DJ; Tan KC
Diabet Med; 2013 Jun; 30(6):702-9. PubMed ID: 23432638
[TBL] [Abstract][Full Text] [Related]
17. Soluble RAGE and skeletal muscle tissue RAGE expression profiles in lean and obese young adults across differential aerobic exercise intensities.
Miranda ER; Mey JT; Blackburn BK; Chaves AB; Fuller KNZ; Perkins RK; Ludlow AT; Haus JM
J Appl Physiol (1985); 2023 Oct; 135(4):849-862. PubMed ID: 37675469
[TBL] [Abstract][Full Text] [Related]
18. Soluble receptor for advanced glycation end products (sRAGE) and endogenous secretory RAGE (esRAGE) in amniotic fluid: modulation by infection and inflammation.
Romero R; Espinoza J; Hassan S; Gotsch F; Kusanovic JP; Avila C; Erez O; Edwin S; Schmidt AM
J Perinat Med; 2008; 36(5):388-98. PubMed ID: 18593373
[TBL] [Abstract][Full Text] [Related]
19. Modifications of Resting Energy Expenditure After Sleeve Gastrectomy.
Bettini S; Bordigato E; Fabris R; Serra R; Dal Pra' C; Belligoli A; Sanna M; Compagnin C; Foletto M; Prevedello L; Fioretto P; Vettor R; Busetto L
Obes Surg; 2018 Aug; 28(8):2481-2486. PubMed ID: 29532316
[TBL] [Abstract][Full Text] [Related]
20. Low levels of serum soluble receptors for advanced glycation end products, biomarkers for disease state: myth or reality.
Prasad K
Int J Angiol; 2014 Mar; 23(1):11-6. PubMed ID: 24627612
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
